ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma—A Children's Oncology Group study
James I. Geller, Joseph G. Pressey, Malcolm A. Smith, Rachel A. Kudgus, Mariana Cajaiba, Joel M. Reid, David Hall, Donald A. Barkauskas, Stephen D. Voss, Steve Y. Cho, Stacey L. Berg, Jeffrey S. Dome, Elizabeth Fox, Brenda J. Weigel
Dive into the research topics of 'ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma—A Children's Oncology Group study'. Together they form a unique fingerprint.